This site is intended only for all Healthcare Professionals residing in South Africa




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usPfizer medical information



Pancreatic neuroendocrine tumours (pNET)Pancreatic neuroendocrine tumours (pNET)ContraindicationsDosage and AdministrationEfficacyInteractionsMechanism of actionPost-marketing ExperiencePrescribing InformationSafetySpecial PopulationsSpecial Warnings and PrecautionsMetastatic renal cell carcinoma (mRCC)Metastatic renal cell carcinoma (mRCC)ContraindicationsDosage and AdministrationEfficacyInteractionsMechanism of actionPost-marketing ExperiencePrescribing InformationSafetySpecial PopulationsSpecial Warnings and PrecautionsGastrointestinal stromal tumour (GIST)Gastrointestinal stromal tumour (GIST)
ContraindicationsDosage and AdministrationEfficacyInteractionsMechanism of actionPost-marketing ExperiencePrescribing InformationSafetySpecial PopulationsSpecial Warnings and Precautions
EfficacySUTENT® (sunitinib) provides a clinically meaningful improvement in PFS1SUTENT® (sunitinib) delivers an OS improvement2 SUTENT® (sunitinib) delivers an OS improvement2 SUTENT® (sunitinib) prolongs mPFS while preserving quality of life1,3,4 Study information

PFS and OS data from a multinational, randomised, double-blind, placebo-controlled phase III trial of SUTENT® (sunitinib) in patients with advanced, well-differentiated pancreatic neuroendocrine tumours, All patients had RECIST-defined disease progression documented within 12 months before baseline, A total of 171 patients were randomly assigned (in a 1:1 ratio) to receive best supportive care with either SUTENT® (sunitinib) 37.5 mg daily or placebo. The primary endpoint was progression-free survival, secondary endpoints included objective response rate, overall survival, patient-reported outcomes and safety, Crossover from placebo to open-label SUTENT® (sunitinib) was permitted following disease progression.1,2 

Study analysed patient-reported outcomes in a randomised, double-blind, Phase III trial of patients with progressive, well-differentiated pNETs receiving SUTENT® (sunitinib) 37.5 mg/day continuous daily dosing. Of the 171 randomised patients, 73 in the SUTENT® (sunitinib) group and 71 in the placebo group had at least one post-baseline QLQ-C30 score, respectively.3

Footnotes:CI: confidence interval; HR: hazard ratio; HRQoL: health-related quality of life; ITT: intention to treat; KM: Kaplan–Meier; mPFS: median progression-free survival; mOS: median overall survival; OS: overall survival; PFS: progression-free survival References:Raymond E, Dahan L, Raoul J, et al. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N Engl J Med 2011;364:501–513.  Raymond E, Niccoli P, Castellano DE, et al. Sunitinib in Patients With Advanced, Progressive Pancreatic Neuroendocrine Tumors: Final Overall Survival Results From a Phase III Randomized Study, Including Adjustment for Crossover. J Clin Oncol 2016;34:(Suppl 4S): Abstract 309. Vinik AI, Banf Y, Raoul J, et al. Patient Patient-reported Outcomes in Patients with Pancreatic Neuroendocrine Tumors (NET) Receiving Sunitinib in a Phase III Trial. J Clin Oncol 2010;28:(Suppl): Abstract 4003. Vinik AI and Raymond E. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib. Ther Adv Gastroenterol 2013;6:396–411.

Copyright ©2024 Pfizer South Africa All rights reserved.

  • The information contained herein is provided for educational purposes only and is not intended to constitute medical advice or replace discussions with a Healthcare Professional. All decisions regarding patient care must be made with a Healthcare Professional, considering the unique characteristics of the patient.
  • While every effort is made to update the information regularly and to offer the most current, correct and clearly expressed information possible, Pfizer cannot be held responsible for any inaccuracy, errors, omissions or misinterpretations.
  • Pfizer, its officers and/or its employees do not accept or take any responsibility whatsoever for any loss, whether direct, indirect or consequential, which may arise from reliance on information contained on these pages and actions resulting therefrom. Any liability that would or could arise as a result of the contents of these pages is hereby excluded to the fullest extent allowed by law.
  • No warranty is given that any files, downloads or applications available via this web site are free of viruses which have the ability to corrupt your system.
  • Any and all information is subject to change without notice.
  • The information provided in this site is intended only for appropriate Healthcare Professionals residing in South Africa.


PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

This site is intended only for all Healthcare Professionals residing in South Africa. If you are a member of the public wishing to access information on a specific medicine, please visit


This website is brought to you by Pfizer South Africa 

Pfizer Laboratories (Pty) Ltd. Company Reg. No. 1954/000781/07. Building 2, 1st Floor, Maxwell Office Park, Magwa Crescent, Waterfall City, Midrand, Johannesburg, South Africa. Tel. No: 0860 PFIZER (734937).


Copyright © 2024. Pfizer Laboratories (Pty) Ltd. All rights reserved

For South Africa Healthcare Professionals *

These pages are not intended for patients or for members of the general public. The healthcare professional webpages contain promotional content.

I confirm that I am a healthcare professional residing in South Africa. If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

Yes No
You are now leaving the PfizerPro South Africa website
You are leaving the South Africa HCP Portal website and being directed to a new website

This website is not controlled by South Africa HCP portal or subject to our privacy policy.

Thank you for visiting our site. We hope your visit was informative and enjoyable
You are now leaving PfizerPro You are now leaving PfizerPro and will be directed to our provider to complete your registration. Any personal information that you may find prepopulated from your PfizerPro profile, or you may provide, will be governed by Privacy Policy. Your data will not be used for any other purpose.